ICU Medical wins arbitration; Pfizer not entitled to up to $225M earn-out from 2017 Hospira deal

ICU MEDICAL INC/DE

Arbitrator ruled on August 7, 2021 that performance targets for HIS earn-out liability were not met.
Pfizer disputed ICU Medical's determination that the $191.3M to $225.0M earn-out was not payable.
Pfizer received no payment in connection with the earn-out liability under the Restated Purchase Agreement.
The dispute arose from the January 2017 acquisition of Pfizer's Hospira Infusion Systems business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.